Rab23 is a potential biological target for treating hepatocellular carcinoma

doi:10.3748/wjg.v13.i7.1010

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 7

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2551)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-10) series, Tables (1-1) series.

Item

Count

PDF

330

HTML

1691

Figures (1-10)

296

Tables (1-1)

234

Sum=2551

Feb 21, 2007 (publication date) through Jan 8, 2025

Times Cited of This Article

Times Cited (44)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Feb 21, 2007; 13(7): 1010-1017
Published online Feb 21, 2007. doi: 10.3748/wjg.v13.i7.1010

Full Size Figure Download Figure

Figure 9 The results of MTT assays. At 48 h and 72 h, growth of Hep-3B cells was inhibited after being interferenced by siRNA against Rab23 gene. the survival rate of the transfection group decreased compared with controls. P < 0.01 vs control group. Again, there was no significant difference between blank and negative control groups, P > 0.05.

Citation: Liu YJ, Wang Q, Li W, Huang XH, Zhen MC, Huang SH, Chen LZ, Xue L, Zhang HW. Rab23 is a potential biological target for treating hepatocellular carcinoma. World J Gastroenterol 2007; 13(7): 1010-1017
URL: https://www.wjgnet.com/1007-9327/full/v13/i7/1010.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i7.1010